Iterum announces topline results from SURE1 trial for uUTI patients

Date: 2020-07-01   Author: Saipriya Iyer  Category: #news

Iterum announces topline results from SURE1 trial for uUTI patients

Iterum Therapeutics plc, a pharmaceutical company, has recently announced the topline results from the SURE1 (Sulopenem for Resistant Enterobacteriaceae) clinical trial. This clinical trial has been conducted for the treatment of uUTI (Uncomplicated Urinary Tract Infections).

Sulopenem is a novel compound that could be the 1st penem antibiotic indicated to treat uUTI. There are 2 independent primary endpoints of the SURE1 trial. The favorable achievement of an endpoint can lead to the marketing approval based on the discussions with the U.S. FDA. Sulopenem reached the primary endpoint in a patient population with quinolones-resistant baseline pathogens, as it demonstrates its superiority as compared to ciprofloxacin for the effective treatment of the uUTI patients.

The results of the trial were highly significant, with a <0.001 p-value. However, sulopenem did not obtain the primary endpoint and was inferior to ciprofloxacin among the 2nd patient population with quinolone-susceptible pathogens. Outcome differences were driven by the asymptomatic bacteriuria post-treatment rate. Sulopenem was well tolerated in SURE1 with a safety profile consistent with the SURE3 and SURE2 trials.

1,670 patients were enrolled in the randomized, double-blind, multi-center clinical trial. The candidates are administered oral sulopenem twice a day for 5 days or the same dose of oral ciprofloxacin for 3 days of treatment. The outcome analysis in both non-susceptible and susceptible patients was conducted to describe the overall results.

Treatment-related adverse impacts were observed among 1,660 patients in the safety population, with 11.9% and 11.4% of patients on ciprofloxacin and sulopenem respectively.

Rate of adverse events were 7.3% and 7.6% diarrhea, 3.4% and 4.0% nausea, and 2.2% and 2.2% headache for patients treated with sulopenem and ciprofloxacin, respectively. Adverse impact discontinuations were seen in 1.1% and 1.5% of patients offered with sulopenem and ciprofloxacin respectively. Additionally, SAE (serious adverse events) were seen in 0.6% of patients that obtained sulopenem and 0.4% of patients that received ciprofloxacin. Based on this data, the company is planning to request a meeting with the U.S. FDA for filing strategy discussion.

Source credit:

https://pipelinereview.com/index.php/2020062975163/Small-Molecules/Iterum-Therapeutics-Announces-Topline-Results-from-its-Phase-3-Clinical-Trial-of-Oral-Sulopenem-for-the-Treatment-of-Uncomplicated-Urinary-Tract-Infections.html



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Cardiac Resynchronization Therapy (CRT) Devices Market to 2026 - Growth Trends and Revenue Statistics

Author: Rahul Varpe

A highly analytical qualitative as well as quantitative evaluation of the Cardiac Resynchronization Therapy (CRT) Devices Market has been covered in this report. The study evaluates the myriad aspects of this industry by taking into consideration ...


Medical Products Market Growth Rate, Revenue and Demand Analysis to 2026

Author: Rahul Varpe

An extremely definite evaluation of the Medical Products Market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have ...


Intensive Care Beds Market - Geography Insights and Opportunity Analysis to 2026

Author: Rahul Varpe

The latest study provides an in-depth analysis of the Intensive Care Beds Market focusing on various market definitions, segmentations, sub-segmentations, products, as well as applications. The report further details of the competitive landscape &...